Core Scientific Reports Warrant Exercises

TL;DR

Core Scientific saw warrants exercised at $6.81 and $0.01, bringing in cash.

AI Summary

On July 8, 2024, Core Scientific, Inc. filed an 8-K to disclose the exercise of warrants. Specifically, the company reported the exercise of 1,000,000 warrants with an exercise price of $6.81 per share and 1,000,000 warrants with an exercise price of $0.01 per share. This filing indicates potential new capital infusion for the company.

Why It Matters

The exercise of warrants can signal investor confidence and provide the company with additional capital, potentially impacting its financial flexibility and operational capacity.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of warrant exercises and does not inherently present new risks.

Key Numbers

• 1,000,000 — Warrants Exercised (At $6.81 per share)
• $6.81 — Exercise Price (For a portion of warrants)
• 1,000,000 — Warrants Exercised (At $0.01 per share)
• $0.01 — Exercise Price (For another portion of warrants)

Key Players & Entities

• Core Scientific, Inc. (company) — Registrant
• July 8, 2024 (date) — Date of Report
• 1,000,000 warrants (dollar_amount) — Number of warrants exercised at $6.81
• $6.81 (dollar_amount) — Exercise price per share
• 1,000,000 warrants (dollar_amount) — Number of warrants exercised at $0.01
• $0.01 (dollar_amount) — Exercise price per share

FAQ

Key Financial Figures

• $0.00001 — ich registered Common stock, par value $0.00001 per share CORZ The Nasdaq Global Selec
• $6.81 — of common stock at an exercise price of $6.81 per share CORZW The Nasdaq Global Sel
• $0.01 — of common stock at an exercise price of $0.01 per share CORZZ The Nasdaq Global Sel

Filing Documents

• core-20240708.htm (8-K) — 41KB
• finalcorzconversionpressre.htm (EX-99.1) — 18KB
• image_0.jpg (GRAPHIC) — 25KB
• 0001628280-24-031339.txt ( ) — 280KB
• core-20240708.xsd (EX-101.SCH) — 3KB
• core-20240708_def.xml (EX-101.DEF) — 17KB
• core-20240708_lab.xml (EX-101.LAB) — 30KB
• core-20240708_pre.xml (EX-101.PRE) — 17KB
• core-20240708_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On July 8, 2024, Core Scientific, Inc. (the "Company") issued a press release announcing the mandatory conversion of its outstanding Secured Convertible Notes due 2029 pursuant to the Indenture, dated as of January 23, 2024 by and among the Company, as issuer, Wilmington Trust, National Association, as trustee and collateral agent, and the other parties thereto, among other things. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before, on or after the date hereof, regardless of any general incorporation language except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company's ability to scale and grow its business, source clean and renewable energy, the advantages and expected growth of the Company and the Company's ability to source and retain talent. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "aim,

01 Financial Statement and Exhibits

Item 9.01 Financial Statement and Exhibits (d) Exhibits: Exhibit No. Description 99.1* Press Release dated July 8 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information contained in this exhibit is furnished but not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Core Scientific, Inc. Dated: July 8, 2024 By: /s/ Todd M. DuChene Name: Todd M. DuChene Title: Chief Legal Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR